FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195032016> ?p ?o ?g. }

• W3195032016 endingPage "1439" @default.
• W3195032016 startingPage "1434" @default.
• W3195032016 abstract "•The clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown.•17.8% of liver transplant recipients, 3.8% of those with cirrhosis and 4.3% of those with CLD without cirrhosis had undetectable antibody levels.•61.3% of liver transplant recipients and 24% of those with CLD (with/without cirrhosis) had poor antibody responses (undetectable/suboptimal).•Liver transplant, immunosuppressive medications and vaccination with a single dose of J&J were associated with poor antibody responses. Background & AimsLiver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials studying the efficacy of vaccines against SARS-CoV-2. Although the clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown, many societies have recommended vaccination of this highly vulnerable patient population.MethodsIn this prospective study, we determined antibody responses to spike protein, 4 weeks after the 2nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver disease (CLD) with and without cirrhosis.ResultsOf the 233 patients enrolled so far, 62 were LT recipients, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Antibody titers were defined as undetectable (<0.40 U/ml), suboptimal (0.40–250 U/ml) and adequate (>250 U/ml). Of the 62 patients who had LT, antibody levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47–212 U/ml) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable antibody levels and 15 had suboptimal (median titer 41.3, range 0.49–221 U/L) antibody responses. Of the 92 patients without cirrhosis, 4 had undetectable antibody levels and 19 had suboptimal (median titer 95.5, range 4.9–234 U/L) antibody responses. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of the Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events.ConclusionsPoor antibody responses after SARS-CoV-2 vaccination were seen in 61% of LT recipients and 24% of those with CLD.Lay summaryThe clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown. We performed a prospective study to evaluate immune responses to COVID-19 vaccines (Moderna, Pfizer or Johnson & Johnson) in 62 liver transplant recipients, 79 patients with cirrhosis and 92 with chronic liver diseases without cirrhosis. We found that 17.8% of liver transplant recipients, 3.8% of those with cirrhosis and 4.3% of those with chronic liver diseases without cirrhosis had undetectable antibody levels. In total, 61.3% of liver transplant recipients and 24% of those with chronic liver diseases (with or without cirrhosis) had poor antibody responses (undetectable or suboptimal). Liver transplantation, use of immunosuppressive medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor antibody responses when adjusted for other factors. Liver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials studying the efficacy of vaccines against SARS-CoV-2. Although the clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown, many societies have recommended vaccination of this highly vulnerable patient population. In this prospective study, we determined antibody responses to spike protein, 4 weeks after the 2nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver disease (CLD) with and without cirrhosis. Of the 233 patients enrolled so far, 62 were LT recipients, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Antibody titers were defined as undetectable (<0.40 U/ml), suboptimal (0.40–250 U/ml) and adequate (>250 U/ml). Of the 62 patients who had LT, antibody levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47–212 U/ml) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable antibody levels and 15 had suboptimal (median titer 41.3, range 0.49–221 U/L) antibody responses. Of the 92 patients without cirrhosis, 4 had undetectable antibody levels and 19 had suboptimal (median titer 95.5, range 4.9–234 U/L) antibody responses. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of the Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events. Poor antibody responses after SARS-CoV-2 vaccination were seen in 61% of LT recipients and 24% of those with CLD." @default.
• W3195032016 created "2021-08-30" @default.
• W3195032016 creator A5044180566 @default.
• W3195032016 creator A5059337045 @default.
• W3195032016 creator A5066936635 @default.
• W3195032016 date "2021-12-01" @default.
• W3195032016 modified "2023-10-06" @default.
• W3195032016 title "Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases" @default.
• W3195032016 cites W3039070431 @default.
• W3195032016 cites W3044002905 @default.
• W3195032016 cites W3045671639 @default.
• W3195032016 cites W3048117004 @default.
• W3195032016 cites W3080747588 @default.
• W3195032016 cites W3089697169 @default.
• W3195032016 cites W3112240189 @default.
• W3195032016 cites W3119391912 @default.
• W3195032016 cites W3121444821 @default.
• W3195032016 cites W3121562869 @default.
• W3195032016 cites W3121564094 @default.
• W3195032016 cites W3126723886 @default.
• W3195032016 cites W3137814380 @default.
• W3195032016 cites W3137955567 @default.
• W3195032016 doi "https://doi.org/10.1016/j.jhep.2021.08.008" @default.
• W3195032016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8387568" @default.
• W3195032016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34454993" @default.
• W3195032016 hasPublicationYear "2021" @default.
• W3195032016 type Work @default.
• W3195032016 sameAs 3195032016 @default.
• W3195032016 citedByCount "117" @default.
• W3195032016 countsByYear W31950320162021 @default.
• W3195032016 countsByYear W31950320162022 @default.
• W3195032016 countsByYear W31950320162023 @default.
• W3195032016 crossrefType "journal-article" @default.
• W3195032016 hasAuthorship W3195032016A5044180566 @default.
• W3195032016 hasAuthorship W3195032016A5059337045 @default.
• W3195032016 hasAuthorship W3195032016A5066936635 @default.
• W3195032016 hasBestOaLocation W31950320161 @default.
• W3195032016 hasConcept C126322002 @default.
• W3195032016 hasConcept C159654299 @default.
• W3195032016 hasConcept C203014093 @default.
• W3195032016 hasConcept C22070199 @default.
• W3195032016 hasConcept C22889606 @default.
• W3195032016 hasConcept C2777075537 @default.
• W3195032016 hasConcept C2777214474 @default.
• W3195032016 hasConcept C2779102576 @default.
• W3195032016 hasConcept C2779609443 @default.
• W3195032016 hasConcept C2908647359 @default.
• W3195032016 hasConcept C2911091166 @default.
• W3195032016 hasConcept C32611913 @default.
• W3195032016 hasConcept C71924100 @default.
• W3195032016 hasConcept C90924648 @default.
• W3195032016 hasConcept C99454951 @default.
• W3195032016 hasConceptScore W3195032016C126322002 @default.
• W3195032016 hasConceptScore W3195032016C159654299 @default.
• W3195032016 hasConceptScore W3195032016C203014093 @default.
• W3195032016 hasConceptScore W3195032016C22070199 @default.
• W3195032016 hasConceptScore W3195032016C22889606 @default.
• W3195032016 hasConceptScore W3195032016C2777075537 @default.
• W3195032016 hasConceptScore W3195032016C2777214474 @default.
• W3195032016 hasConceptScore W3195032016C2779102576 @default.
• W3195032016 hasConceptScore W3195032016C2779609443 @default.
• W3195032016 hasConceptScore W3195032016C2908647359 @default.
• W3195032016 hasConceptScore W3195032016C2911091166 @default.
• W3195032016 hasConceptScore W3195032016C32611913 @default.
• W3195032016 hasConceptScore W3195032016C71924100 @default.
• W3195032016 hasConceptScore W3195032016C90924648 @default.
• W3195032016 hasConceptScore W3195032016C99454951 @default.
• W3195032016 hasIssue "6" @default.
• W3195032016 hasLocation W31950320161 @default.
• W3195032016 hasLocation W31950320162 @default.
• W3195032016 hasLocation W31950320163 @default.
• W3195032016 hasOpenAccess W3195032016 @default.
• W3195032016 hasPrimaryLocation W31950320161 @default.
• W3195032016 hasRelatedWork W1965380659 @default.
• W3195032016 hasRelatedWork W2052378569 @default.
• W3195032016 hasRelatedWork W2071360760 @default.
• W3195032016 hasRelatedWork W2101325366 @default.
• W3195032016 hasRelatedWork W2138148194 @default.
• W3195032016 hasRelatedWork W2369560021 @default.
• W3195032016 hasRelatedWork W2605146346 @default.
• W3195032016 hasRelatedWork W2734795904 @default.
• W3195032016 hasRelatedWork W3125479117 @default.
• W3195032016 hasRelatedWork W4296385692 @default.
• W3195032016 hasVolume "75" @default.
• W3195032016 isParatext "false" @default.
• W3195032016 isRetracted "false" @default.
• W3195032016 magId "3195032016" @default.
• W3195032016 workType "article" @default.